TNG917
TNG917 is a potent, selective EHMT1/2 inhibitor with oral activity. TNG917 reduces H3K9me2-mediated transcriptional repression, restores interferon-stimulated gene expression, promotes the secretion of T-cell chemokines such as CXCL10, and converts immunologically cold tumors into T-cell inflamed tumors. TNG917 is applicable to studies on immunologically cold tumors, colorectal cancer, anti-tumor immunity, interferon signaling pathways and epigenetic immune escape.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2923223-81-6
- 分子式: C20H24FN5O
- 分子量:369.44
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Histone Methyltransferase アイソフォーム固有の製品をすべて表示
More
生物活性
|
EHMT1 |
EHMT2 |
TNG917 dose-dependently reduces H3K9me2 levels in cells, with a cellular potency IC50 of approximately 2 nM, and induces CXCL10 secretion with an AC50 of approximately 5 nM[1].
TNG917 (1-10 μM) is a selective inhibitor of EHMT1/2, and exerts no significant inhibitory effect on the other 37 tested methyltransferases at concentrations of 1 μM and 10 μM[1].
TNG917 relieves H3K9-mediated transcriptional repression, restores the expression of interferon-stimulated genes, and induces the secretion of T cell chemokines such as CXCL10[2].
TNG917 (1 μM) upregulates interferon-stimulated genes in human colorectal cancer cell line HT29, mimicking the phenotype of EHMT1/2 double knockout[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
TNG917 (10-100 mg/kg, p.o.; once daily for 5 consecutive days) exhibits dose-dependent plasma exposure in female C57BL/6 mice bearing MC38 tumors, and reduces H3K9me2 levels in tumor tissues at 2 and 8 h after the final administration[1].
Combination treatment with TNG917 (3, 30 mg/kg, p.o.; once daily for 6 consecutive days) and Pembrolizumab (HY-P9902A) (10 mg/kg, i.p.; once weekly for a total of 3 times) increases the infiltration of total T cells, CD8+ T cells, CD4+ T cells and M1 macrophages, and reduces M2 macrophages within CT26 tumors[1].
Combination treatment with TNG917 (30 mg/kg, p.o.) and Pembrolizumab (10 mg/kg, i.p.) induces chemokines such as Ccl8, Ccl5 and Ccl3, as well as interferon-stimulated gene-related signals in CT26 tumor tissues[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (female, MC38 tumor-bearing)[1]
-
Dosage:10 mg/kg; 30 mg/kg; 100 mg/kg
-
Administration:p.o.; daily; 5 days
-
Result:Produced dose-dependent plasma exposure and reduced tumor H3K9me2 levels at 2 and 8 h after the final dose.
-
Animal Model:NOG (HT29 human colon carcinoma tumor-bearing，immunodeficient)[1]
-
Dosage:3 mg/kg; 10 mg/kg; 30 mg/kg
-
Administration:p.o.; once daily
-
Result:Inhibited tumor growth, with tumor growth inhibition of 50% and 84% at 10 and 30 mg/kg, respectively.
-
Animal Model:BALB/c (female，CT26 syngeneic tumor-bearing)[1]
-
Dosage:TNG917: 3 mg/kg; 30 mg/kg; Pembrolizumab: 10 mg/kg
-
Administration:TNG917: p.o.; once daily for 6 days;Pembrolizumab: i.p.; once weekly for 3 doses; tumors collected on Day 7
-
Result:Increased intratumoral T cells, CD8+ T cells, CD4+ T cells and M1 macrophages, and decreased M2 macrophages.
化学情報
-
CAS 番号 2923223-81-6
-
分子量 369.44
-
分子式 C20H24FN5O
-
SMILES
FC(C(C1=CCNCCC1)=C2OCCC2=C3)=C3NC4=NC(C)=CC(NC)=N4
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
TNG917 関連分類
HY-184500 関連分類
Powered by Bioz